✦ LIBER ✦

Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?

✍ Scribed by Stearns, Vered; Rae, James M.

Book ID: 120462003
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 168 KB
Volume: 10
Category: Article
ISSN: 1574-6976
DOI: 10.1017/S1462399408000896

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5171 POSTER First Results From a Study A

5171 POSTER First Results From a Study Analyzing CYP2D6 Genotypes and Tamoxifen Metabolites in a Canadian Population With Endocrine Responsive Breast Cancer

✍ Sousa, B.; Nasim, S.; Cole, D.; Wong, B.; Hill, K.; Vandenberghe, H.; Ueng, S.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Prevalent breast cancer patients with a

Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users

✍ A. S. Dieudonné; D. Lambrechts; B. Claes; T. Vandorpe; H. Wildiers; D. Timmerman 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 224 KB

p27Kip1 is a predictive factor for tamox

p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients

✍ Maria Stendahl; Sofie Nilsson; Caroline Wigerup; Karin Jirström; Per Ebbe Jönsso 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 489 KB

## Abstract The cell‐cycle regulating protein p27^Kip1^ (p27) has dual roles by acting as both a cdk inhibitor and as an assembly factor for different cdk complexes. Loss of p27 has been linked to malignant features in tumours; however, the exact role of p27 deregulation in breast cancer regarding

Response to hormonal therapy as a progno

Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy

✍ Sewa S. Legha; Aman U. Buzdar; Terry L. Smith; Kenneth D. Swenerton; Gabriel N. 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 688 KB

P1 Circulating adiponectin levels as a p

P1 Circulating adiponectin levels as a predictive factor of breast cancer in a double-blind 2×2 phase II trial of low-dose tamoxifen and fenretinide for breast cancer prevention

✍ A. Guerrieri Gonzaga; S. Gandini; H. Johansson; D. Macis; P. Magni; E. Dozio; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Hypoxia inducible factor-1α is a prognos

Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response

✍ Åsa Kronblad; Karin Jirström; Lisa Rydén; Bo Nordenskjöld; Göran Landberg 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 765 KB

## Abstract Hypoxia is common in many solid tumours, including breast cancer. Hypoxia triggers the expression of hypoxia inducible factor‐1α (HIF‐1α), and HIF‐1α has been associated with an impaired prognosis in breast cancer and down‐regulation of the oestrogen receptor (ER), potentially affecting